secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001558370-25-002097
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Capricor's BLA for deramiocel for DMD cardiomyopathy with Priority Review, PDUFA Aug 31, 2025
--------------------------------------------------------------------------------

- FDA accepted BLA for deramiocel (cell therapy) to treat Duchenne muscular dystrophy cardiomyopathy.
- Priority Review granted; PDUFA target date August 31, 2025.
- FDA has not identified any potential review issues at this time.
- If approved, deramiocel would be first approved therapy for DMD cardiomyopathy.
- Supports Phase 2 HOPE-2 and OLE trials vs. natural history data from FDA-funded dataset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/0001558370-25-002097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer